<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05060419</url>
  </required_header>
  <id_info>
    <org_study_id>FL058-II-01</org_study_id>
    <nct_id>NCT05060419</nct_id>
  </id_info>
  <brief_title>Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections</brief_title>
  <official_title>Phase Ⅱ, Randomized, Double-Blind,Double-Dummy Study Evaluating Safety,Tolerability,Efficacy of Meropenem-FL058 in Adult Patients With Complicated Urinary Tract Infections, Including Acute Pyelonephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qilu Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2, randomised, double-blind,double-dummy study in hospitalised adults with complicated&#xD;
      urinary tract infection (cUTI), including acute pyelonephritis.Treatment duration for each&#xD;
      cohort was 7 to 14 days. Patients were not permitted to switch to oral therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 8, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 29, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-Blind,Double-Dummy</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients in the Microbiological Modified Intent to Treat (m-MITT) Population who achieve overall treatment success at Test Of Cure (TOC).</measure>
    <time_frame>5 to 9 days post-End of Treatment</time_frame>
    <description>Treatment success is defined as the composite of clinical outcome of Cure and the microbiological outcome of Eradication.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Complicated Urinary Tract Infection</condition>
  <condition>Acute Pyelonephritis</condition>
  <arm_group>
    <arm_group_label>Meropenem-FL058 (180min infusion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Piperacillin-Tazobactan (30min infusion)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem- FL058</intervention_name>
    <description>Meropenem-FL058(Meropenem 1000mg plus FL058 1000mg)q8h&#xD;
Meropenem-FL058(Meropenem 2000mg plus FL058 1000mg)q8h</description>
    <arm_group_label>Meropenem-FL058 (180min infusion)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin -tazobactam</intervention_name>
    <description>Piperacillin-tazobactam (piperacillin 4 g plus tazobactam 0.5 g)q8h</description>
    <arm_group_label>Piperacillin-Tazobactan (30min infusion)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>180min</description>
    <arm_group_label>Piperacillin-Tazobactan (30min infusion)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>30min</description>
    <arm_group_label>Meropenem-FL058 (180min infusion)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients, aged 18 ~ 75 years (inclusive);；&#xD;
&#xD;
          2. Acute pyelonephritis or other complicated urinary tract infection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients needing concomitant systemic antimicrobial agents in addition to those&#xD;
             designated in the various study treatment groups;&#xD;
&#xD;
          2. Fungal urinary tract infection;&#xD;
&#xD;
          3. History of allergic to any carbapenem, cephalosporin, penicillin, other β -lactam&#xD;
             drugs or other β -lactamase inhibitors;&#xD;
&#xD;
          4. Pregnant or breastfeeding women;&#xD;
&#xD;
          5. Inability to tolerate intravenous fluids, due to medical reasons, of 1050 mL per day&#xD;
             required for study drug administration;&#xD;
&#xD;
          6. Unable or unwilling, in the judgment of the Investigator, to comply with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huang Haihui, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ju Yunfei, MM</last_name>
    <phone>+86-0531-55821309</phone>
    <email>yunfei.ju@qilu-pharma.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 18, 2021</study_first_submitted>
  <study_first_submitted_qc>September 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2021</study_first_posted>
  <last_update_submitted>September 18, 2021</last_update_submitted>
  <last_update_submitted_qc>September 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Pyelonephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Piperacillin, Tazobactam Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

